PIPELINE

Scaling new heights in early disease interception

Early cancer
screening

GASTROClear Test

The world's first RNA blood test for early detection of gastric cancer

Infectious, cardiovascular, and metabolic diseases

Fortitude Kit

A SARS-CoV-2 RT-PCR test for accurate testing of COVID-19

Discovery and
development

ID3EAL Suite

Versatile market-leading microRNA research solutions for scientists

In the pipeline:

5 tests for early cancer
detection:

Gastric Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Ovarian Cancer

Liver Cancer

In the pipeline:

1
test for
infectious disease.
3 tests for cardiovascular and
metabolic diseases

COVID-19

Heart Failure

Pulmonary Hypertension

Sepsis

Insulin Resistance

In the pipeline:

1
new ID3EAL microRNA knowledge panel.

Cancer microRNA Panel

Biofluid microRNA Panel

PanoramiR Disease Relevant Panel

Viral microRNA Panel

Early cancer
screening

GASTROClear Test

The world's first RNA blood test for early detection of gastric cancer

In the pipeline:

5 tests for early cancer
detection:

Gastric Cancer

Lung Cancer

Breast Cancer

Colorectal Cancer

Ovarian Cancer

Liver Cancer

Infectious, cardiovascular, and metabolic diseases

Fortitude Kit

A SARS-CoV-2 RT-PCR test for accurate testing of COVID-19

In the pipeline:

1
test for
infectious disease.
3 tests for cardiovascular and
metabolic diseases

COVID-19

Heart Failure

Pulmonary Hypertension

Sepsis

Insulin Resistance

Early cancer
screening

ID3EAL Suite

Versatile market-leading microRNA research solutions for scientists

In the pipeline:

1
new ID3EAL microRNA knowledge panel.

Cancer microRNA Panel

Biofluid microRNA Panel

PanoramiR Disease Relevant Panel

Viral microRNA Panel

Read more about our latest and key scientific publications here.

24 Mar 2021

Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms. 

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

Copyright © 2021 MiRXES Pte Ltd. All rights reserved.
Scroll to Top